Drug interactions : Individuals taking medications that affect nitric oxide pathways or blood flow should exercise particular caution, as theoretical interactions are possible, though unconfirmed in clinical settings
It is important to note that having potential risk factors does not preclude tirzepatide use, but rather indicates the need for patient education, appropriate monitoring during treatment initiation, and readily available emergency management resources
It is essential to monitor anti-JC virus antibody titers and adjust infusion frequency based on the individual risk profile
Patients who may particularly benefit from GLP-1 receptor agonists include those with type 2 diabetes and established cardiovascular disease, obesity, or chronic kidney disease (where SGLT2 inhibitors are not suitable or as additional therapy)
Patients should be advised to maintain adequate hydration, and renal function should be monitored if they become unwell